ANI Pharmaceuticals (ANIP)

• Market cap: $1.53B
• 1 day: 0.08%
• 5 days: 3.40%
• 1 month: 5.78%
• 3 months: 18.91%
• 6 months: 21.04%
• Year to date: 27.74%
• 1 year: 7.30%
• 5 years: 77.01%
• 10 years: 16.14%
• Sector: Healthcare
• Industry: Drug Manufacturers - Specialty & Generic

About: ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid-dose products. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended-release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. The company operates in two segments which include Rare Diseases and Brands, Generics, and Others. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.

Employees: 897

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

13% more repeat investments, than reductions

Existing positions increased: 68 | Existing positions reduced: 60

1.79% more ownership

Funds ownership: 90.19% [Q3] → 91.98% (+1.79%) [Q4]

0% more first-time investments, than exits

New positions opened: 31 | Existing positions closed: 31

1% less funds holding

Funds holding: 207 [Q3] → 204 (-3) [Q4]

6% less capital invested

Capital invested by funds: $1.14B [Q3] → $1.07B (-$72.4M) [Q4]

69% less call options, than puts

Call options by funds: $188K | Put options by funds: $597K

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $65 8% downside
• Avg. target: $82 16% upside
• High target: $94 33% upside

5 analyst ratings

• positive: 4 80%
• neutral: 1 20%
• negative: 0 0%

Truist Securities Gregory Fraser 0% 1-year accuracy 0 / 2 met price target	8% downside $65	Hold Maintained	21 Apr 2025
Guggenheim Vamil Divan 40% 1-year accuracy 12 / 30 met price target	21% upside $86	Buy Reiterated	11 Apr 2025
HC Wainwright & Co. Oren Livnat 57% 1-year accuracy 28 / 49 met price target	33% upside $94	Buy Reiterated	17 Mar 2025
Jefferies Glen Santangelo 45% 1-year accuracy 5 / 11 met price target	13% upside $80	Buy Initiated	14 Mar 2025
JP Morgan Ekaterina Knyazkova 100% 1-year accuracy 1 / 1 met price target	20% upside $85	Overweight Initiated	12 Mar 2025